Recombinant Rhesus monkey ADRB3 Protein, His-tagged
Cat.No. : | ADRB3-261R |
Product Overview : | Recombinant Rhesus monkey ADRB3 full length or partial length protein was expressed. |
- Specification
- Gene Information
- Related Products
Source : | Mammalian Cells |
Species : | Rhesus monkey |
Tag : | His |
Form : | Liquid or lyophilized powder |
Endotoxin : | < 1.0 EU per μg of the protein as determined by the LAL method. |
Purity : | >80% |
Notes : | This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications. |
Storage : | Store it at +4 ºC for short term. For long term storage, store it at -20 ºC~-80 ºC. |
Storage Buffer : | PBS buffer |
Gene Name : | ADRB3 adrenoceptor beta 3 [ Macaca mulatta (Rhesus monkey) ] |
Official Symbol : | ADRB3 |
Synonyms : | ADRB3; beta-3 adrenergic receptor; adrenergic, beta-3-, receptor; beta-3 adrenoceptor; beta-3 adrenoreceptor; beta-3-adrenergic receptor; |
Gene ID : | 699129 |
mRNA Refseq : | NM_001044730 |
Protein Refseq : | NP_001038195 |
MIM : | |
UniProt ID : | Q28524 |
Products Types
◆ Recombinant Protein | ||
ADRB3-31C | Recombinant Cynomolgus Monkey ADRB3 Protein, His (Fc)-Avi-tagged | +Inquiry |
ADRB3-2436H | Recombinant Human ADRB3 Protein, His (Fc)-Avi-tagged | +Inquiry |
ADRB3-89R | Recombinant Rhesus Macaque ADRB3 Protein, His (Fc)-Avi-tagged | +Inquiry |
ADRB3-201R | Recombinant Rat ADRB3 Protein, His (Fc)-Avi-tagged | +Inquiry |
ADRB3-367M | Recombinant Mouse ADRB3 Protein, His (Fc)-Avi-tagged | +Inquiry |
◆ Lysates | ||
ADRB3-8998HCL | Recombinant Human ADRB3 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (15)
Ask a questionSome potential risks or drawbacks of ADRB3-targeted therapies include an increased risk of adverse cardiovascular events, such as heart attack or stroke. Additionally, the long-term effects and safety of these therapies are not well established, and more research is needed to fully understand their potential risks and benefits.
No, there are currently no FDA-approved ADRB3-targeted therapies for medical use in the United States. However, several investigational drugs are in development and under clinical trials for conditions such as obesity and diabetes.
There is limited research suggesting that ADRB3 proteins may play a role in certain types of cancer, including breast cancer and melanoma. However, the mechanisms of their action and the potential clinical implications are still unclear and require further investigation.
Yes, several natural substances have been shown to activate or modulate ADRB3 proteins, including caffeine, bitter orange, and capsaicin (found in chili peppers). However, the efficacy and safety of using these substances for ADRB3-targeted therapies are not well established.
Some potential benefits of ADRB3-targeted therapies include weight loss, improved insulin sensitivity, and reduced risk of cardiovascular disease. These therapies may also have fewer side effects than some other weight loss medications, such as gastrointestinal issues or psychiatric effects.
ADRB3 proteins are involved in regulating glucose metabolism and insulin sensitivity, and their activation has been shown to increase glucose uptake and improve insulin sensitivity in muscle and adipose tissue. Therefore, ADRB3-targeted therapies are being explored as potential treatments for type 2 diabetes. However, more research is needed to determine the safety and efficacy of these interventions, as previous agonists have been associated with adverse effects, such as increased heart rate and blood pressure.
Yes, ADRB3 proteins are believed to play a role in the metabolic and physiological responses to exercise, particularly in relation to energy metabolism and fat oxidation. Exercise has also been shown to increase the expression of ADRB3 proteins in adipose tissue, which may contribute to its beneficial effects on metabolic health.
ADRB3 activation has been shown to increase athletic performance by improving endurance, energy metabolism, and muscle function. However, the use of ADRB3-targeted therapies for doping purposes is banned by the World Anti-Doping Agency, as these agents can also have adverse effects on cardiovascular function and may pose a risk to athletes' health.
Yes, genetic mutations in the ADRB3 gene have been identified and linked to various conditions, including obesity, metabolic syndrome, and hypertension. These mutations can affect the function and expression of ADRB3 proteins, leading to changes in lipid and glucose metabolism, energy expenditure, and cardiovascular function.
Yes, researchers are exploring the use of ADRB3-targeted therapies for treating obesity, diabetes, and other metabolic disorders. However, there is still much to learn about the role of ADRB3 proteins in these conditions and the potential risks and benefits of targeting them with medications.
Ongoing research areas related to ADRB3 proteins include the mechanisms of their action in adipose tissue and other organs, the role of ADRB3 genetic variations in metabolic disorders, and the development and testing of new ADRB3-targeted therapies for obesity, diabetes, and other conditions.
ADRB3 proteins can interact with a variety of signaling pathways, including the adrenergic, insulin, and inflammatory pathways. For example, ADRB3 activation can stimulate lipolysis and increase fatty acid oxidation in adipose tissue, which can help prevent obesity and improve insulin sensitivity. Additionally, ADRB3 activation can modulate inflammation and immune function, which may have implications for the treatment of autoimmune and inflammatory diseases.
There has been considerable interest in developing ADRB3-targeted therapies for weight loss, as activation of these receptors has been shown to increase energy expenditure, promote fat oxidation, and improve insulin sensitivity. However, clinical trials with ADRB3 agonists have yielded mixed results and have been associated with adverse effects, such as increased heart rate and blood pressure. Therefore, more research is needed to determine the safety and efficacy of ADRB3-targeted weight loss interventions.
ADRB3-targeted therapies aim to increase energy expenditure and promote fat oxidation, rather than simply reducing appetite or inhibiting nutrient absorption. They may also improve insulin sensitivity and metabolic function, which can have broader health benefits beyond weight loss. However, the safety and efficacy of these therapies remain uncertain, and more research is needed to determine their long-term effects on health outcomes.
One of the main challenges in developing ADRB3-targeted therapies is achieving selectivity and specificity, as ADRB3 proteins are structurally similar to other adrenergic receptors and can activate multiple signaling pathways. Another challenge is determining the optimal dose and treatment duration to achieve therapeutic effects without causing adverse effects. Additionally, more research is needed to elucidate the long-term safety and efficacy of these therapies in diverse patient populations.
Customer Reviews (4)
Write a reviewThe protein is pure, stable, and consistently performs at a high standard, ensuring that my results will be reliable and reproducible.
The ADRB3 protein provided by the manufacturer is of exceptional quality and is precisely what I require to conduct my experiments accurately.
Their expertise and responsiveness have made the entire process smoother and more efficient, allowing me to focus entirely on my experiments.
the technical support team provided by the manufacturer is outstanding and has been incredibly helpful in resolving any issues or concerns that may arise during my research.
Ask a Question for All ADRB3 Products
Required fields are marked with *
My Review for All ADRB3 Products
Required fields are marked with *
Inquiry Basket